Compare AbCellera Biologics Inc (ABCL) vs Genuine Parts Company (GPC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Genuine Parts Company — how do they compare? AbCellera Biologics Inc trades at $7.15 (market cap $2.35B), while Genuine Parts Company trades at $124.94 (market cap $17.71B). The key difference: Genuine Parts Company is far larger — about 7.5× AbCellera Biologics Inc's market cap, and Genuine Parts Company pays a 3.3% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | GPC | |
|---|---|---|
Market Cap | $2.35B | $17.71B |
Sector | Health | Consumer Cyclical |
52-Week High | $8.12 | $149.26 |
52-Week Low | $2.78 | $92.47 |
Enterprise Value | $1.99B | $23.92B |
Dividend Yield | — | 3.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
GPC trades at $128.67, down 2.94% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported mixed earnings, missing in Q3 and Q4 2025 but beating in Q1 2026, with Q2 2026 results due July 21, 2026. Financials show revenue growth to $24.3B in 2025 but a sharp decline in net income margin to 0.24%, while the P/E ratio of 292.41 reflects high valuation relative to earnings. A dividend of $1.06 per share is scheduled for payment on July 2, 2026.
The outlook is cautious due to weak profitability and high P/E, but analyst consensus is a Buy with a $133 price target, suggesting modest upside. Risks include earnings volatility and competitive pressures in the automotive parts sector. The stock's near-term direction hinges on Q2 2026 earnings, with support at $126 and resistance at $131.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Genuine Parts Company
Genuine Parts sells automotive parts (about two thirds of net sales) and industrial components. The company sells vehicle parts to commercial and retail customers through roughly 9,700 stores worldwide, most of which are independently owned. Its industrial unit, primarily operating under the Motion Industries banner in the United States, supplies bearings, power transmission, industrial automation, hydraulic, and pneumatic components to maintenance, repair, and OEM clients.
Read more on GPC →
